My interest in multiple myeloma and plasma cell dyscrasias dates back to medical school, and remains the focus of my clinical practice and research presently. I have developed and led clinical trials investigating new therapies and novel combinations of medications for patients with all stages of myeloma, as well as for patients with primary systemic amyloidosis. KCI currently has one of the largest myeloma and amyloidosis research programs in the Midwest, with several hundred patients seen annually, including over a hundred undergoing autologous stem cell transplant. I also collaborate with basic science researchers here at Karmanos who conduct studies exploring the biology of these diseases.